ArticleScience translational medicine2021
Fourteen-day PET/CT imaging to monitor drug combination activity in treated individuals with tuberculosis.
Open access · greenAbstract read
In one paragraph
Article in Science translational medicine, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers, 1 of them a synthesis that pooled it.
0numbers the graph read from it
0cells of the map it votes in
32citing papers in PubMed, 1 pooled it
2.2field-weighted citation impact, top 10% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
32 citing papers in PubMed, 1 synthesis or guideline pooled it, 45 citations in OpenAlex.
- EANM/SNMMI guideline/procedure standard for [European journal of nuclear medicine and molecular imaging · 2025Guideline
- Clinical testing of drug treatment shortening in patients with TB using PET/CT imaging of lung lesions.Science translational medicine · 2026Trial
- PET-CT outcomes from a randomised controlled trial of rosuvastatin as an adjunct to standard tuberculosis treatment.Nature communications · 2024Trial
- A first-in-class leucyl-tRNA synthetase inhibitor, ganfeborole, for rifampicin-susceptible tuberculosis: a phase 2a open-label, randomized trial.Nature medicine · 2024Trial
- Sputum lipoarabinomannan (LAM) as a biomarker to determine sputum mycobacterial load: exploratory and model-based analyses of integrated data from four cohorts.BMC infectious diseases · 2022Trial
- Trial
- Inflammation Precedes Paradoxical Reactions in HIV-Negative Patients With Pulmonary Tuberculosis.Open forum infectious diseases · 2026Article
- Essential role of MHC II in the antitubercular efficacy of pyrazinamide.Antimicrobial agents and chemotherapy · 2026Article
- PET/CT imaging of tuberculosis lung lesions in marmosets treated with different drug regimens aligns with human clinical outcomes.Science translational medicine · 2026Article
- Using Imaris to rigorously track PET-defined sites of lung inflammation inAmerican journal of diagnostic imaging · 2026Article
- Inflammatory Macrophages Associate With Tissue Injury and Fibrosis in a Mouse Model of Tuberculosis.The Journal of infectious diseases · 2025Article
- Early and opposing neutrophil and CD4 T cell responses shape pulmonary tuberculosis pathology.The Journal of experimental medicine · 2025Article
- PET imaging of mycobacterial infection: transforming the pipeline for tuberculosis drug development.Npj imaging · 2025Review
- Review
- Recent Breakthroughs in PET-CT Multimodality Imaging: Innovations and Clinical Impact.Bioengineering (Basel, Switzerland) · 2024Review
- PET/CT guided tuberculosis treatment shortening: a randomized trial.medRxiv : the preprint server for health sciences · 2024Article
- A mouse model of TB-associated lung fibrosis reveals persistent inflammatory macrophage populations during treatment.bioRxiv : the preprint server for biology · 2024Article
- Therapeutic developments for tuberculosis and nontuberculous mycobacterial lung disease.Nature reviews. Drug discovery · 2024Review
- Does PET-CT Have a Role in the Evaluation of Tuberculosis Treatment in Phase 2 Clinical Trials?The Journal of infectious diseases · 2024Review
- Restocking the tuberculosis drug arsenal.Nature medicine · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
24 authors at 10 institutions in 2 countries.
Yingda L XieDivision of Infectious Diseases, Department of Medicine, Rutgers New Jersey Medical School, Newark, NJ 07103, USA.ORCID 0000-0001-5587-4731
Veronique R de JagerTASK Applied Science, Cape Town 7500, South Africa.ORCID 0000-0001-6389-5575
Ray Y ChenTuberculosis Research Section, Laboratory of Clinical Immunology and Microbiology, Division of Intramural Research, National Institute of Allergy and Infectious Disease, National Institutes of Health, Bethesda, MD 20892, USA.ORCID 0000-0001-6344-1442
Lori E DoddBiostatistics Research Branch, Division of Clinical Research, National Institute of Allergy and Infectious Disease, National Institutes of Health, Bethesda, MD 20892, USA.ORCID 0000-0002-3433-5429
Praveen ParipatiImaging Group, NET ESolutions Inc., McLean, VA 22102, USA.ORCID 0000-0001-8024-4782
Laura E ViaTuberculosis Research Section, Laboratory of Clinical Immunology and Microbiology, Division of Intramural Research, National Institute of Allergy and Infectious Disease, National Institutes of Health, Bethesda, MD 20892, USA.ORCID 0000-0001-6074-9521
Dean FollmannBiostatistics Research Branch, Division of Clinical Research, National Institute of Allergy and Infectious Disease, National Institutes of Health, Bethesda, MD 20892, USA.ORCID 0000-0003-4073-0393
Jing WangClinical Monitoring Research Program Directorate, Frederick National Laboratory for Cancer Research, Frederick, MD 21702, USA.
Keith LumbardClinical Monitoring Research Program Directorate, Frederick National Laboratory for Cancer Research, Frederick, MD 21702, USA.
Saher LahouarImaging Group, NET ESolutions Inc., McLean, VA 22102, USA.
Stephanus T MalherbeDepartment of Science and Technology-National Research Foundation Centre of Excellence for Biomedical Tuberculosis Research, South African Medical Research Council Centre for Tuberculosis Research, Division of Molecular Biology and Human Genetics, Department of Biomedical Sciences, Faculty of Medicine and Health Sciences, Stellenbosch University, Cape Town 7600, South Africa.
Jenna AndrewsMicrobial Pathogenesis, Yale University, New Haven, CT 06520, USA.
Xiang YuTuberculosis Research Section, Laboratory of Clinical Immunology and Microbiology, Division of Intramural Research, National Institute of Allergy and Infectious Disease, National Institutes of Health, Bethesda, MD 20892, USA.
Lisa C GoldfederTuberculosis Research Section, Laboratory of Clinical Immunology and Microbiology, Division of Intramural Research, National Institute of Allergy and Infectious Disease, National Institutes of Health, Bethesda, MD 20892, USA.ORCID 0000-0002-5507-1776
Ying CaiTuberculosis Research Section, Laboratory of Clinical Immunology and Microbiology, Division of Intramural Research, National Institute of Allergy and Infectious Disease, National Institutes of Health, Bethesda, MD 20892, USA.ORCID 0000-0001-9145-2333
Kriti AroraTuberculosis Research Section, Laboratory of Clinical Immunology and Microbiology, Division of Intramural Research, National Institute of Allergy and Infectious Disease, National Institutes of Health, Bethesda, MD 20892, USA.ORCID 0000-0002-4373-0367
Andre G LoxtonDepartment of Science and Technology-National Research Foundation Centre of Excellence for Biomedical Tuberculosis Research, South African Medical Research Council Centre for Tuberculosis Research, Division of Molecular Biology and Human Genetics, Department of Biomedical Sciences, Faculty of Medicine and Health Sciences, Stellenbosch University, Cape Town 7600, South Africa.ORCID 0000-0003-0659-9803
Naadira VankerTASK Applied Science, Cape Town 7500, South Africa.
Michael DuvenhageClinical Monitoring Research Program Directorate, Frederick National Laboratory for Cancer Research, Frederick, MD 21702, USA.ORCID 0000-0003-3769-220X
Jill WinterCatalysis Foundation for Health, San Ramon, CA 94583, USA.ORCID 0000-0003-1345-3546
Taeksun SongInstitute of Infectious Disease and Molecular Medicine, University of Cape Town, Cape Town 7925, South Africa.ORCID 0000-0003-4478-4161
Gerhard WalzlDepartment of Science and Technology-National Research Foundation Centre of Excellence for Biomedical Tuberculosis Research, South African Medical Research Council Centre for Tuberculosis Research, Division of Molecular Biology and Human Genetics, Department of Biomedical Sciences, Faculty of Medicine and Health Sciences, Stellenbosch University, Cape Town 7600, South Africa.
Andreas H DiaconTASK Applied Science, Cape Town 7500, South Africa.ORCID 0000-0001-8641-6792
Clifton E BarryTuberculosis Research Section, Laboratory of Clinical Immunology and Microbiology, Division of Intramural Research, National Institute of Allergy and Infectious Disease, National Institutes of Health, Bethesda, MD 20892, USA. cbarry@niaid.nih.gov.ORCID 0000-0002-2927-270X
National Institute of Allergy and Infectious Diseases · USUniversity of Cape Town · ZAFrederick National Laboratory for Cancer Research · USSouth African Medical Research Council · ZANETE (United States) · USTask Applied Science · ZACatalysis Foundation for Health · USRutgers, The State University of New Jersey · USStellenbosch University · ZAYale University · US
Funding
WORK ORDER 126643 B539 EXPAND IC SUITE75N91019D00024 · NIAID · LEIDOS BIOMEDICAL RESEARCH, INC. · PI BRISCOE, LYNN · 2019 to 2025
$3932.6MInternational Tuberculosis Research in ChinaZIAAI001081 · NIAID · NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES · PI BARRY, CLIFTON · 2010 to 2025
$12.2MTuberculosis studies in South AfricaZIAAI001214 · NIAID · NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES · PI BARRY, CLIFTON · 2016 to 2017
$1.0MIntramural NIH HHS ZIA AI001214NCI NIH HHS 75N91019D00024
Abstract
Early bactericidal activity studies monitor daily sputum bacterial counts in individuals with tuberculosis (TB) for 14 days during experimental drug treatment. The rate of change in sputum bacterial load over time provides an informative, but imperfect, estimate of drug activity and is considered a critical step in development of new TB drugs. In this clinical study, 160 participants with TB received isoniazid, pyrazinamide, or rifampicin, components of first-line chemotherapy, and moxifloxacin individually and in combination. In addition to standard bacterial enumeration in sputum, participants underwent 2-deoxy-2-[
Indexed as
TuberculosisTuberculosis, PulmonaryAntitubercular AgentsDrug CombinationsDrug Therapy, CombinationFluorodeoxyglucose F18HumansPositron Emission Tomography Computed TomographyAntitubercular AgentsDrug CombinationsFluorodeoxyglucose F18
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.